- Home
- MLKN vs CVAC Comparison
MLKN vs CVAC Comparison
Compare MLKN & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLKN
- CVAC
- Stock Information
- Founded
- MLKN 1905
- CVAC 2000
- Country
- MLKN United States
- CVAC Germany
- Employees
- MLKN N/A
- CVAC N/A
- Industry
- MLKN Office Equipment/Supplies/Services
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- MLKN Consumer Discretionary
- CVAC Health Care
- Exchange
- MLKN Nasdaq
- CVAC Nasdaq
- Market Cap
- MLKN 1.4B
- CVAC 1.2B
- IPO Year
- MLKN N/A
- CVAC 2020
- Fundamental
- Price
- MLKN $20.43
- CVAC $5.34
- Analyst Decision
- MLKN
- CVAC Hold
- Analyst Count
- MLKN 0
- CVAC 3
- Target Price
- MLKN N/A
- CVAC $6.83
- AVG Volume (30 Days)
- MLKN 347.7K
- CVAC 482.2K
- Earning Date
- MLKN 09-23-2025
- CVAC 11-11-2025
- Dividend Yield
- MLKN 3.56%
- CVAC N/A
- EPS Growth
- MLKN N/A
- CVAC N/A
- EPS
- MLKN N/A
- CVAC 1.01
- Revenue
- MLKN $3,669,900,000.00
- CVAC $599,540,810.00
- Revenue This Year
- MLKN $4.74
- CVAC N/A
- Revenue Next Year
- MLKN $3.64
- CVAC $24.04
- P/E Ratio
- MLKN N/A
- CVAC $5.30
- Revenue Growth
- MLKN 1.14
- CVAC 675.15
- 52 Week Low
- MLKN $15.25
- CVAC $2.37
- 52 Week High
- MLKN $28.33
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- MLKN 46.97
- CVAC 42.37
- Support Level
- MLKN $20.08
- CVAC $5.33
- Resistance Level
- MLKN $21.11
- CVAC $5.41
- Average True Range (ATR)
- MLKN 0.59
- CVAC 0.04
- MACD
- MLKN -0.14
- CVAC -0.01
- Stochastic Oscillator
- MLKN 16.75
- CVAC 15.38
About MLKN MillerKnoll Inc.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.